| 產(chǎn)品編號(hào) | bs-7627R-BF350 |
| 英文名稱(chēng) | Rabbit Anti-NS5ATP9/BF350 Conjugated antibody |
| 中文名稱(chēng) | BF350標(biāo)記的丙型肝炎病毒非結(jié)構(gòu)蛋白5A反式激活蛋白9抗體 |
| 別 名 | L5 antibody PAF; HCV NS5A transactivated protein 9; Hepatitis C virus NS5A transactivated protein 9; NS5 ATP9; NS5ATP9; OEATC 1; Overexpressed in anaplastic thyroid carcinoma 1; p15(PAF); p15PAF; PCNA associated factor; PCNA-associated factor; PAF15_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 染色質(zhì)和核信號(hào) 細(xì)胞凋亡 細(xì)菌及病毒 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Pig, Cow, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 12kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human NS5ATP9/KIAA0101 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: NS5ATP9/PAF/p15(PAF) is involved in protection of cells from UV-induced cell death and is also a Hepatitis C NS5A up-regulation gene which may play a role in the pathogenesis of HCV-associated hepatocellular carcinoma. Function: PCNA-binding protein that acts as a regulator of DNA repair during DNA replication. Following DNA damage, the interaction with PCNA is disrupted, facilitating the interaction between monoubiquitinated PCNA and the translesion DNA synthesis DNA polymerase eta (POLH) at stalled replisomes, facilitating the bypass of replication-fork-blocking lesions. Also acts as a regulator of centrosome number. Subunit: Interacts (when monoubiquitinated at Lys-15 and Lys-24) with PCNA. Interacts with isoform 2/p33ING1b of ING1. Interacts with BRCA1. Subcellular Location: Nucleus. Cytoplasm, perinuclear region. Note=Following DNA damage, localizes to DNA damage sites. Colocalizes with centrosomes in perinuclear region. Tissue Specificity: Expressed predominantly in liver, pancreas and placenta. Not detected in heart or brain. Highly expressed in a number of tumors, especially esophageal tumors, in anaplastic thyroid carcinomas, adrenocortical carcinomas, and in non-small-cell lung cancer lines. Post-translational modifications: Monoubiquitinated at Lys-15 and Lys-24 during normal S phase, promoting its association with PCNA. Also diubiquitinated at these 2 sites. Following DNA damage, monoubiquitin chains at Lys-15 and Lys-24 are probably extended, leading to disrupt the interaction with PCNA. Polyubiquitinated by the APC/C complex at the mitotic exit, leading to its degradation by the proteasome. Database links: UniProtKB/Swiss-Prot: Q15004.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
